December 8, 2023

To

**BSE Limited** 

Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal Street,

Mumbai - 400 001

To

The National Stock Exchange of India Ltd

Exchange Plaza,

Bandra Kurla Complex, Bandra (E)

Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and

Takeovers) Regulations, 2011

In compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I would like to inform you that Dr. Davuluri Rama Mohan Rao has sold 4,00,000 equity shares of Neuland Laboratories Limited (i.e. 3.12 % stake) on December 8, 2023. The relevant disclosure under the aforementioned regulation is enclosed as Annexure 1.

This is for your information and records.

Thanking you,

Yours faithfully,

or. Davuluri Rama Mohan Rac

Encl: As above

CC: The Company Secretary, Neuland Laboratories Limited

11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills.

Hyderabad, 500033, Telangana, India

Annexure - 1

## Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Neuland Laboratories Limited		
Name(s) of the Acquirer/Seller and Persons Acting in Concert (PAC) with the acquirer	Dr. Davuluri Ram Mohan Rao		
Whether the Acquirer/Seller belongs to Promoter/Promoter group	Promoter		
Name(s) of the Stock Exchange(s) where	1. BSE Limited		
the shares of TC are Listed	2. The National Stock Exchange of India Ltd		
Details of the <del>acquisition</del> /disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/sale under consideration, holding of:  a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	31,69,974	24.71	24.71
c) Voting rights (VR) otherwise than by equity shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
Total (a+b+c+d)	31,69,974	24.71	24.71
a) Shares carrying voting rights acquired/sold b) VRs acquired otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting	4,00,000	3.12	3.12
rights in the TC (specify holding in each category) acquired  d) Shares in the nature of encumbrance (pledge/ lien/ nondisposal undertaking/ others)			
Total (a+b+c+/-d)	4,00,000	3.12	3.12

After the acquisition/sale, holding of:				
<ul> <li>a) Shares carrying voting rights</li> <li>b) VRs otherwise than by equity shares</li> <li>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting</li> </ul>	27,69,974	21.59	21.59	
rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrances (pledge/ lien/ non-disposal undertaking/ others)				
Total (a+b+c+d)	27,69,974	21.59	21.59	
Mode of acquisition/sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market	t		
Date of acquisition/sale of shares / VR or date of receipt of intimation of allotment of shares, which ever is applicable	08/12/2023			
Equity share capital / total voting capital of the TC before the said acquisition/sale	1,28,29,889 Equity Shares			
Equity share capital/ total voting capital of the TC after the said acquisition/sale	1,28,29,889 Equity Shares			
Total diluted share/voting capital of the TC after the said acquisition/sale	1,28,29,889	Equity Shares	•	

## Note

(\*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature

Dr. Davuluri Ramamohan Rao

Place: Hyderabad Date: 08/12/2023